KNSA insider transfers shares to family trusts at $0 price

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals (KNSA): The Chairman & CEO reported bona fide gifts (Code G) of Class A ordinary shares. On 11/12/2025, 111,794 shares were gifted; on 11/13/2025, 60,000 shares were gifted. These entries were at a stated price of $0 per share.

After the transactions, reported holdings were 0 shares direct, and indirect balances included 51,794 shares held by The Anglia 2013 Revocable Trust, 60,000 shares held by The Patel Family Irrevocable Trust of 2025, and 109,795 shares held by The Marina 2016 Irrevocable Trust.

Insider Trade Summary

343,588 shares gifted

Mixed 5 txns

Insider Patel Sanj K

Role CHAIRMAN & CEO

Type	Security	Shares	Price	Value
Gift	Class A Ordinary Share	60,000	$0.00	--
Gift	Class A Ordinary Share	60,000	$0.00	--
Gift	Class A Ordinary Share	111,794	$0.00	--
Gift	Class A Ordinary Share	111,794	$0.00	--
holding	Class A Ordinary Share	--	--	--

Holdings After Transaction: Class A Ordinary Share — 51,794 shares (Indirect, Held by The Anglia 2013 Revocable Trust); Class A Ordinary Share — 0 shares (Direct)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patel Sanj K

(Last) (First) (Middle)

105 PICCADILLY, SECOND FLOOR

(Street)

LONDON X0 W1J 7NJ

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHAIRMAN & CEO

3. Date of Earliest Transaction (Month/Day/Year)
11/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Share	11/12/2025		G		111,794	D	$0	0	D
Class A Ordinary Share	11/12/2025		G		111,794	A	$0	111,794	I	Held by The Anglia 2013 Revocable Trust
Class A Ordinary Share	11/13/2025		G		60,000	D	$0	51,794	I	Held by The Anglia 2013 Revocable Trust
Class A Ordinary Share	11/13/2025		G		60,000	A	$0	60,000	I	Held by The Patel Family Irrevocable Trust of 2025
Class A Ordinary Share								109,795	I	Held by The Marina 2016 Irrevocable Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Douglas Barry, Attorney-in-Fact	11/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did KNSA’s insider report on Form 4?

The Chairman & CEO reported bona fide gifts (Code G) of Class A ordinary shares on 11/12/2025 (111,794 shares) and 11/13/2025 (60,000 shares).

What were the gift amounts and dates for KNSA?

111,794 shares were gifted on 11/12/2025 and 60,000 shares were gifted on 11/13/2025, both at a stated price of $0 per share.

How many KNSA shares does the insider hold directly after the transactions?

Direct holdings were reported as 0 shares following the transactions.

What are the indirect KNSA holdings reported after the transactions?

51,794 shares held by The Anglia 2013 Revocable Trust, 60,000 by The Patel Family Irrevocable Trust of 2025, and 109,795 by The Marina 2016 Irrevocable Trust.

What does transaction code G mean on KNSA’s Form 4?

Code G indicates a bona fide gift of the issuer’s securities.

Was a 10b5-1 trading plan indicated for these KNSA transactions?

The excerpt includes the 10b5-1 checkbox language, but no selection is shown in the provided content.